The Correlation Between Neutrophil-to-lymphocyte Ratio, Carcinoembryonic Antigen, and Carbohydrate Antigen 153 Levels with Chemotherapy-related Cognitive Impairment in Early-stage Breast Cancer Patients

Overview

Journal Front Med (Lausanne)

Specialty General Medicine

Date 2022 Sep 12

PMID 36091709

Authors

Sheng Yu

Jingjing Zhao

Menglian Wang

Guo Cheng

Wen Li

Lingxue Tang

Senbang Yao

Lulian Pang

Xiangxiang Yin

Yanyan Jing

Huaidong Cheng

Affiliations

Soon will be listed here.

Abstract

Background: Early detection and intervention are of great significance to the clinical management of cancer-related diseases. Peripheral blood biomarkers [e.g., neutrophil-to-lymphocyte ratio (NLR), carcinoembryonic antigen (CEA), and carbohydrate antigen 153 (CA153)] are obtained in real-timely, conveniently, and less invasively, and proved to availably predicted the disease states and prognosis of various cancers, including breast cancer (BC). Inflammation and poor disease management promote cognitive impairment. Chemotherapy-related cognitive impairment (CRCI) hazard long-term survival and quality of life (QOL) of BC patients, but its correlation with NLR, CEA, and CA153 is not clear.

Purpose: This study aimed to investigate changes in NLR, CEA, and CA153 levels before and after chemotherapy and their correlation with CRCI in patients with early-stage BC.

Materials And Methods: The 187 patients with BC who were measured for NLR, CEA, and CA153 values within the first 24 hours of admission, were assigned into two groups: the before/after chemotherapy group (BCG/ACG). The ACG was assigned into two subgroups based on the cognitive assessment results: the cognitive normal/impaired group (CNG/CIG). Patients' self-perceived cognitive impairments were evaluated using a mini-mental state examination (MMSE), prospective and retrospective memory (PM and RM) questionnaire (PRMQ), and functional assessment of cancer therapy-cognitive function version 3 (FACT-Cog, version 3, including CogPCI, CogOth, CogPCA, and CogQOL). Their QOL was also evaluated.

Results: The NLR and CA153 levels were elevated after chemotherapy (BCG vs ACG: = -1.996 and -1.615, = 0.046 and 0.106, respectively), and significantly elevated in patients with CRCI (BCG vs CIG: = -2.444 and -2.293, = 0.015 and 0.022; respectively). However, there was not reach significant difference in CEA levels between the four groups. In addition, there was a weak to moderate correlation between peripheral blood biomarkers (NLR, CEA, and CA153) levels and CRCI ( = -0.404, -0.205, -0.322; respectively; < 0.001). Cognitive impairment scores (MMSE, PM, RM, and FACT-Cog) had a strong correlation with QOL in patients with early-stage BC ( = -0.786, 0.851, 0.849, and 0.938; respectively; < 0.001).

Conclusion: NLR and CA153 m be valuable diagnostic adjuncts of CRCI, and CRCI has a strong correlation with QOL in patients with early-stage BC.

Citing Articles

Impact of NDUFAF6 on breast cancer prognosis: linking mitochondrial regulation to immune response and PD-L1 expression.

Jiang B, Wu S, Zeng L, Tang Y, Luo L, Ouyang L Cancer Cell Int. 2024; 24(1):99.

PMID: 38459583 PMC: 10921816. DOI: 10.1186/s12935-024-03244-1.

References

Templeton A, McNamara M, Seruga B, Vera-Badillo F, Aneja P, Ocana A . Prognostic role of neutrophil-to-lymphocyte ratio in solid tumors: a systematic review and meta-analysis. J Natl Cancer Inst. 2014; 106(6):dju124. DOI: 10.1093/jnci/dju124. View

Ahmed G, Khedr E, Hamad D, Meshref T, Hashem M, Aly M . Long term impact of Covid-19 infection on sleep and mental health: A cross-sectional study. Psychiatry Res. 2021; 305:114243. PMC: 8507572. DOI: 10.1016/j.psychres.2021.114243. View

Sung H, Ferlay J, Siegel R, Laversanne M, Soerjomataram I, Jemal A . Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA Cancer J Clin. 2021; 71(3):209-249. DOI: 10.3322/caac.21660. View

Li W, Zhang Q, Cai Y, Chen T, Cheng H . The COMT Genetic Factor Regulates Chemotherapy-Related Prospective Memory Impairment in Survivors With HER2-/+ Breast Cancer. Front Oncol. 2022; 12:816923. PMC: 8861381. DOI: 10.3389/fonc.2022.816923. View

Ma Y, Wang H, Zhao W, Li Y, Wang J, Chen X . Prognostic Value of Combined Lactate Dehydrogenase, C-Reactive Protein, Cancer Antigen 153 and Cancer Antigen 125 in Metastatic Breast Cancer. Cancer Control. 2022; 29:10732748211053150. PMC: 8743925. DOI: 10.1177/10732748211053150. View

Lv L, Mao S, Dong H, Hu P, Dong R . Pathogenesis, Assessments, and Management of Chemotherapy-Related Cognitive Impairment (CRCI): An Updated Literature Review. J Oncol. 2020; 2020:3942439. PMC: 7333028. DOI: 10.1155/2020/3942439. View

Song X, Liang B, Wang C, Shi S . Clinical value of color Doppler ultrasound combined with serum CA153, CEA and TSGF detection in the diagnosis of breast cancer. Exp Ther Med. 2020; 20(2):1822-1828. PMC: 7388249. DOI: 10.3892/etm.2020.8868. View

Orszaghova Z, Mego M, Chovanec M . Long-Term Cognitive Dysfunction in Cancer Survivors. Front Mol Biosci. 2021; 8:770413. PMC: 8713760. DOI: 10.3389/fmolb.2021.770413. View

Patel M, McCully C, Godwin K, Balis F . Plasma and cerebrospinal fluid pharmacokinetics of intravenous temozolomide in non-human primates. J Neurooncol. 2003; 61(3):203-7. DOI: 10.1023/a:1022592913323. View

10.

Wardill H, Mander K, Van Sebille Y, Gibson R, Logan R, Bowen J . Cytokine-mediated blood brain barrier disruption as a conduit for cancer/chemotherapy-associated neurotoxicity and cognitive dysfunction. Int J Cancer. 2016; 139(12):2635-2645. DOI: 10.1002/ijc.30252. View

11.

Nassif E, Arsene-Henry A, Kirova Y . Brain metastases and treatment: multiplying cognitive toxicities. Expert Rev Anticancer Ther. 2019; 19(4):327-341. DOI: 10.1080/14737140.2019.1582336. View

12.

Kiesl D, Kuzdas-Sallaberger M, Fuchs D, Brunner S, Kommenda R, Tischler C . Protocol for the Exercise, Cancer and Cognition - The ECCO-Study: A Randomized Controlled Trial of Simultaneous Exercise During Neo-/Adjuvant Chemotherapy in Breast Cancer Patients and Its Effects on Neurocognition. Front Neurol. 2022; 13:777808. PMC: 8990905. DOI: 10.3389/fneur.2022.777808. View

13.

Crawford J, Smith G, Maylor E, Della Sala S, Logie R . The Prospective and Retrospective Memory Questionnaire (PRMQ): Normative data and latent structure in a large non-clinical sample. Memory. 2003; 11(3):261-75. DOI: 10.1080/09658210244000027. View

14.

Di Gioia D, Stieber P, Schmidt G, Nagel D, Heinemann V, Baur-Melnyk A . Early detection of metastatic disease in asymptomatic breast cancer patients with whole-body imaging and defined tumour marker increase. Br J Cancer. 2015; 112(5):809-18. PMC: 4453962. DOI: 10.1038/bjc.2015.8. View

15.

Anderson R, Lambertini M, Hall P, Wallace W, Morrison D, Kelsey T . Survival after breast cancer in women with a subsequent live birth: Influence of age at diagnosis and interval to subsequent pregnancy. Eur J Cancer. 2022; 173:113-122. DOI: 10.1016/j.ejca.2022.06.048. View

16.

Hamer J, McDonald R, Zhang L, Verma S, Leahey A, Ecclestone C . Quality of life (QOL) and symptom burden (SB) in patients with breast cancer. Support Care Cancer. 2016; 25(2):409-419. DOI: 10.1007/s00520-016-3417-6. View

17.

Lange M, Joly F, Vardy J, Ahles T, Dubois M, Tron L . Cancer-related cognitive impairment: an update on state of the art, detection, and management strategies in cancer survivors. Ann Oncol. 2019; 30(12):1925-1940. PMC: 8109411. DOI: 10.1093/annonc/mdz410. View

18.

Duijf P, Nanayakkara D, Nones K, Srihari S, Kalimutho M, Khanna K . Mechanisms of Genomic Instability in Breast Cancer. Trends Mol Med. 2019; 25(7):595-611. DOI: 10.1016/j.molmed.2019.04.004. View

19.

Chung N, Walker A, Dhillon H, Vardy J . Mechanisms and Treatment for Cancer- and Chemotherapy-Related Cognitive Impairment in Survivors of Non-CNS Malignancies. Oncology (Williston Park). 2019; 32(12):591-8. View

20.

Andre F, Ismaila N, Allison K, Barlow W, Collyar D, Damodaran S . Biomarkers for Adjuvant Endocrine and Chemotherapy in Early-Stage Breast Cancer: ASCO Guideline Update. J Clin Oncol. 2022; 40(16):1816-1837. DOI: 10.1200/JCO.22.00069. View